Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Issued (2023 - 2025)

Monte Rosa Therapeutics' Shares Issued history spans 3 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Shares Issued fell 89.13% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.7 million, down 88.55%, while the annual FY2025 figure was $5.7 million, 88.55% down from the prior year.
  • Shares Issued reached $5.4 million in Q4 2025 per GLUE's latest filing, up from $362000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $49.3 million in Q4 2024 to a low of -$262000.0 in Q3 2024.
  • Average Shares Issued over 3 years is $6.7 million, with a median of $530000.0 recorded in 2024.
  • The largest YoY upside for Shares Issued was 1266.67% in 2024 against a maximum downside of 123.8% in 2024.
  • A 3-year view of Shares Issued shows it stood at $23.0 million in 2023, then soared by 114.58% to $49.3 million in 2024, then plummeted by 89.13% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Shares Issued are $5.4 million (Q4 2025), $362000.0 (Q3 2025), and -$14000.0 (Q2 2025).